[Ca2+]i and PKC-α are involved in the inhibitory effects of Ib, a novel nonpeptide AngiotensinII subtype AT1 receptor antagonist, on AngiotensinII-induced vascular contraction in vitro

Biochemical and Biophysical Research Communications

Volumn 364, Issue 1, 2007, Pages 118-123

  Wang, Yu ^a   Wang, Wei ^a   Wang, Qiujuan ^a   Wu, Jinhui ^a   Xu, Jinyi ^a   Wu, Xiaoming ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Ca2+ i; AngII; AT1 receptor antagonist; Ib; PKC ; Vascular contraction

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN II DERIVATIVE; ANGIOTENSIN II IODINE 125; CALCIUM DERIVATIVE; IB; PROTEIN KINASE C ALPHA; UNCLASSIFIED DRUG; 5 N BUTYL 4 (4 (2 (1H TETRAZOL 5 YL) 1H PYRROL 1 YL)PHENYLMETHYL) 2,4 DIHYDRO 2 (2,6 DICHLOROPHENYL) 3H 1,2,4 TRIAZOL 3 ONE; 5-N-BUTYL-4-(4-(2-(1H-TETRAZOL-5-YL)-1H-PYRROL-1-YL)PHENYLMETHYL)-2,4-DIHYDRO-2-(2,6-DICHLOROPHENYL)-3H-1,2,4-TRIAZOL-3-ONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM; LOSARTAN; TETRAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM; HORMONE BINDING; IC 50; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE FIBER; VASCULAR RING; VASCULAR SMOOTH MUSCLE; ANIMAL; CYTOLOGY; DRUG EFFECT; METABOLISM; MUSCLE CONTRACTION; PHYSIOLOGY; THORACIC AORTA;

ORYCTOLAGUS CUNICULUS;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; CALCIUM; LOSARTAN; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PROTEIN KINASE C-ALPHA; RABBITS; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; TRIAZOLES;

EID: 35348955896     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.09.101     Document Type: Article

References (29)

1. Williams G.H. Converting-enzyme inhibitors in the treatment of hypertension. N. Engl. J. Med. 319 (1988) 1517-1525
2. Brown N.J., and Vaughan D.E. Angiotensin-converting enzyme inhibitors. Circulation 97 (1998) 1411-1420
3. Chung O., and Unger T. Pharmacology of angiotensin receptors and AT1 receptor blockers. Basic Res. Cardiol. 93 Suppl 2 (1998) 15-23
4. Carson P., Giles T., Higginbotham M., Hollenberg N., Kannel W., and Siragy H.M. Angiotensin receptor blockers: evidence for preserving target organs. Clin. Cardiol. 24 (2001) 183-190
5. Kirch W., Horn B., and Schweizer J. Comparison of angiotensin II receptor antagonists. Eur. J. Clin. Invest. 31 (2001) 698-706
6. Xu J.Y., Zhou Y.X., and Wu X.M. Synthesis and bioactivity of 1-aryl-3-alkyl-1,4-dihydro-4-substitued-5H-1,2,4,-triazolinones-5. J. China Pharm. Univ. 30 (1999) 323-327
7. Wu J.H., Wang Q.J., Hu S., Xu J.Y., and Wu X.M. Antihypertensive effects of a new angiotensin type 1 receptor antagonist 1b on rats. J. China Pharm. Univ. 36 (2005) 563-566
8. Zhang J., Wang Q.J., Xu J.Y., and Wu X.M. Effects of a new angiotensin type 1 receptor antagonist 1b on the cardiac hypertrophy induced by l-thyroxin in rat. J. China Pharm. Univ. 37 (2006) 157-160
9. Yan B., Wang G., Sun J., Li X., Zheng Y., Ai H., Lv H., Wu X., and Xu J. Identification of the major metabolites of 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one, a new angiotensin type 1 receptor antagonist, in rat bile by HPLC-diode array detection-MS and HPLC-MS/MS. Biomed. Chromatogr. (2007)
10. Lee S.H., Jung Y.S., Lee B.H., Yun S.I., Yoo S.E., and Shin H.S. Characterization of AngiotensinII antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist. J. Cardiovasc. Pharmacol. 33 (1999) 367-374
11. Wienen W., Hauel N., Van Meel J.C., Narr B., Ries U., and Entzeroth M. Pharmacological characterization of the novel nonpeptide AngiotensinII receptor antagonist, BIBR 277. Br. J. Pharmacol. 110 (1993) 245-252
12. Panek R.L., Lu G.H., Overhiser R.W., Major T.C., Hodges J.C., and Taylor D.G. Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J. Pharmacol. Exp. Ther. 273 (1995) 753-761
13. Bond R.A., Ornstein A.G., and Clarke D.E. Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation. J. Pharmacol. Exp. Ther. 249 (1989) 401-410
14. Dostal D.E., Murahashi T., and Peach M.J. Regulation of cytosolic calcium by angiotensins in vascular smooth muscle. Hypertension 15 (1990) 815-822
15. Touyz R.M., Tolloczko B., and Schiffrin E.L. Mesenteric vascular smooth muscle cells from spontaneously hypertensive rats display increased calcium responses to AngiotensinII but not to endothelin-1. J. Hypertens. 12 (1994) 663-673
16. Touyz R.M., and Schiffrin E.L. AngiotensinII regulates vascular smooth muscle cell pH, contraction, and growth via tyrosine kinase-dependent signaling pathways. Hypertension 30 (1997) 222-229
17. Ruan X., and Arendshorst W.J. Calcium entry and mobilization signaling pathways in ANGII-induced renal vasoconstriction in vivo. Am. J. Physiol. 270 (1996) F398-F405
18. 2+ from intracellular stores. Hypertension 29 (1997) 222-227
19. Iversen B.M., and Arendshorst W.J. ANGII and vasopressin stimulate calcium entry in dispersed smooth muscle cells of preglomerular arterioles. Am. J. Physiol. 274 (1998) F498-F508
20. Touyz R.M., He G., Deng L.Y., and Schiffrin E.L. Role of extracellular signal-regulated kinases in AngiotensinII-stimulated contraction of smooth muscle cells from human resistance arteries. Circulation 99 (1999) 392-399
21. Rembold C.M. Regulation of contraction and relaxation in arterial smooth muscle. Hypertension 20 (1992) 129-137
22. Neusser M., Tepel M., and Zidek W. AngiotensinII responses after protein kinase C activation in vascular smooth muscle cells of spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 21 (1993) 749-753
23. Sachinidis A., Ko Y., Weisser P., Meyer zu Brickwedde M.K., Dusing R., Christian R., Wieczorek A.J., and Vetter H. EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the AngiotensinII-induced responses in vascular smooth muscle cells. J. Hypertens. 11 (1993) 155-162
24. Touyz R.M., and Schiffrin E.L. Signal transduction mechanisms mediating the physiological and pathophysiological actions of AngiotensinII in vascular smooth muscle cells. Pharmacol. Rev. 52 (2000) 639-672
25. Arnaudeau S., Macrez-Lepretre N., and Mironneau J. Activation of calcium sparks by AngiotensinII in vascular myocytes. Biochem. Biophys. Res. Commun. 222 (1996) 809-815
26. 2+ antagonist-insensitive coronary smooth muscle contraction involves activation of epsilon-protein kinase C-dependent pathway. Am. J. Physiol. Cell. Physiol. 285 (2003) C1454-C1463
27. 2+ antagonist-insensitive coronary smooth muscle contraction via activation of epsilon-protein kinase C. Hypertension 43 (2004) 897-904
28. Horowitz A., Menice C.B., Laporte R., and Morgan K.G. Mechanisms of smooth muscle contraction. Physiol. Rev. 76 (1996) 967-1003
29. i threshold for translocation of the alpha-protein kinase C isoform. Am. J. Physiol. 266 (1994) C1544-C1551